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SUMMARY: Analogs of thyrotropin-releasing hormone (Glp-His-Pro--NH2, 
TRH) have been prepared which contain thioamide moieties in the pyroglutamic 
acid ring, the carboxyamide proline terminus, andin both positions (dithio). 
These compounds have been tested für TSH-releasing activities (in vitro and in 
viuo), and for binding to TRH receptors in rat pituitary and cortex. The 
monothionated analoge showed no significant differences in TSH-releasing 
potency from TRH either in vitro or in vivo. However, with two thioamide 
replacements the potency decreases about 50%. Significantly, in terms of receptor 
selectivity, thionation has resulted in differentiation between brain receptors 
(p~tuitary and cortex). The Pro'V[CSNH2) and dithio analogs were more selective 
(higher affinity to pituitary receptors) than the parent hormone, while the analog 
containing a thioamide replacement in the pyroglutamyl ring had lower affinity 
and was not selective. These results suggest that the subtle exchange of sulphur 
for oxygen can have an important impact on both receptor selectivity and affinity 
within 8 biologically active peptide. 0 1992 Academic Press, Inc. 
Design of new analogs of naturally occurring peptides through 
modification of the peptide backbone has become increasingly important (1-3). 
Peptide backbone modifications are used to obtain more active analogs, to achieve 
enzymatic stability, to improve or change receptor selectivity, and to change 
transport properties. The complex changes in the biological profile of analogs can 
be rationally analyzed and understood especially when the modified peptide 
adopts a conformation similar to that ofthe non-modified peptide (4). 
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One ofthe most subtle and conservative variations within peptides is the 
thioamide surrogate, 'lf[CSNH], in which the amide oxygen has been replaced by 
sulfur. Various physical studies (5-8) indicate that thioamides are highly 
isosteric with the amides (mainly the Z planar configuration), except that 
incorporation of the sulfur changes the hydrogen-bonding properties (9). Thus, 
the NH in the thioamide is a stronger donor and the C=S is a weaker acceptor 
than the NH and the C=O in the amides, respectively. 
In spite of the physical compatibilities, biological activities of thiopeptides 
are often unpredictable. The C-terminal thioamide analog of oxytocin 
([GlY'lf[CSNH2J9JOT), displayed 6% oxytoxic and 1.5% A VD activity compared to 
oxytocin (10). Also the C-terminal thioamide analog of growth hormone-
releasing peptide (11), the leucine enkephalin thionated in the 1-2 position (12), 
and the thio analog of dermorphin (13) have proven less active than their parent 
peptide, whereas the C-terminal thioamide analog of thyrotropin-releasing 
hormone is almost equipotent with TRH in terms ofits TSH-releasing activity (14). 
On the other band, thionation of the 2-3 bond in leucine enkephalin resulted 
in a more active and selective (higher affinity to a than to µ opioid receptors) 
analog than the parent peptide (12). We have also reported (15) the biological 
activity of multithionated cyclic analogs of enkephalin based on the Schiller-
DiMaio (16) structure, H-Tyr--<yclo(NLD-Lys-Gly-Phe-Leu). As the number of 
sulfurs increased, biological activities decreased, but the compounds displayed 
increasing a selectivity. 
Because of the interesting influence of sulfur(s} on the receptor selectivity in 
the series of cyclic enkephalins ( 15) and the high activity of previously synthesized 
[Pro'lf(CSNH2)3]TRH (14), we decided to examine the effect ofthe thioamide moiety 
in a series of new TRH analogs (17,18). In this paper, we describe the synthesis 
and biological activity profiles of the thionated analogs of thyrotropin-releasing 
hormone (I), containing the thioamide in the pyroglutamic acid ring, 
carboxyamide proline terminus, andin both positions (dithio analog IV) as shown 
in Figure 1. 
0 0 y 
" " " a~~.9e-C-NH-1R-e-~~yH-C~NH2 
X~ C~ '-../ l~ l : X=Y=O r II : X=O,Y=S 
H III: X=S,Y=O 
IV: X=Y=S 
Figure 1. Thionated analogs of TRH. 
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MATERIALS AND METHODS 
All compounds were eynthesized using solution phase methods. The 
protected peptides Glt>=His(DNP)-Pro'V[CSNH2l. TFA•His(DNP}-Pro-NH2, and 
TFA•Hie(DNP)-Pro'V[CSNH2] were syntheeized using routes analogous to those 
previously reported (-14). 
Top-His--Pro-NH2 (III) (Top = thiopyroglutamic acid) and 
Top-His-Pro\ll[CSNHz] (IV) were prepared by two methods beginning with 
thionation of Glp-OtBu and Glp-OTcp (Tcp = 2,4,5-trichlorophenyl) by 
Lawesson's Reagent (LR) in THF at 25·c to afford Toi>:--QtBu and To}>-ÜTcp in 
94% and 74% yield, respectively. In the first method, following deprotection with 
4N HCl/dio~ane, TopOH was coupled to TFA•His(DNP)-Pro--NH2 and 
TFA • His(DNP)-Pro\jf[CSNH2l with 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) in D:MF to yield after 
workup Top-His(DNP)-Pro-NH2 and Top-His(DNP)-Pro'l'[CSNH.2] in 76% and 
71% yields, respectively. 
In the second method, Top-QTcp was coupled to TF A • His(DNP)-Pro--NH2, 
and TFA•His(DNP}-Pro'1'[CSNH2J in DMF in the presence ofHOBt to obtain 
Top-His(DNP}-Pro-NH2 and Top--His(DNP)-Pro\if[CSNH2] in 86% and 80% 
yields, resp~ctively. 
Cleavage of the DNP protecting_grpups by mercaptoethanol in DMF 
generated crude Gli>:-His-Prm41[CSNH2] (II), Top-His-Pro-NH2 (III) and 
Top-His-Pro'!'[CSNHz] (!V) were purified by normal phase column 
chromatography followed by gel filtration on Sephadex G-10. 
Final purification was accomplished by reversed phase chromatography on 
a Vydac C-18 column (2.5 x 25 cm) using a solution of CH3CN in 0.05% TFA in 
H20 (5% for II, 4% for III, and 9% for IV) at a flow rate of 3.5 ml/min. 
Purity of the analogs was assessed with two separate TLC (Kiesegel 60) 
systems: (A) CHClg/MeOH, 1:3; (B) n-BuOH/AcOHIH20/AcOEt, 1:1:1:1, and by 
analytical reversed phase HPLC (a linear giradient of 5-35% of CHaCN in 0.05% 
TFA over 30 min at a flow rate of 1.0 ml/min, column: Vydac 4.6 x 250 mm, C-18). 
The peptides were further characterized by amino acid analysis and fast 
atom bombardment mass spectrometry (F ABMS). 
Glp--His-Pro)jr[CSNH,2] (II): TLC ßr: 0.47 (A); 0.39 (B). Analytical RP-HPLC tR: 
9.99 min. Amino acid analysis: Glu 1.06; His 1.05, Pro 1.00. FABMS: 379 (calc. 
M+ + H, 379). 
Top---His-Pro-NH,z (III): TLC Rr: 0.45 (A); 0.38 (B). Analytical RP-HPLC t&: 9.62 
min. Amino acid analysis: Glu 0.98, His 1.19, Pro 1.00. FABMS: 379 (calc. M+ + 
H, 379). 
Top-His-ProwrCSNHi (IV): TLC Rr: 0.51(A);0.43 (ß). Analytical RP-HPLC tR: 
14.59 min. Amino aci analysis: Glu 0.97, His 1.08, Pro 1.00. FABMS: 395 (calc. 
M++H, 395). 
In vitro assays: Adult female rats were sacrifi.ced by decapitation and anterior 
pituitaries removed as quickly as possible, minced, and placed in an Erlenmeyer 
flask containing trypsin in Gey's buffer at 37"C with 5% C02 for 35 min. Cells 
were washed and suspended in deoxyribonuclease I and gassed for 4 min more. 
Calls were washed and triturated with a lima bean inhibitor, centrifuged, 
suspended in DMEM and plated at 2.6 x 105 cells/m.l. All peptides were dissolved 
in water, diluted in 0.1% gelatin water and added to the wells in a 30 µl volume. 
Each value is the mean of 3 ± sem. 
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In ujuo aasays: Female CD-1 strain rats about 26 daye of age were used for theae 
studies. Rats were maintained at a constant temperature (25"C) on a 14-h light, 
10-h dark cycle and food and water were available ad libitum. AJl peptidea were 
dissolved in water (1:1), diluted in 0.1% gelatin saline and administered ac to 
conscious rats. Trunk blood was coUected by decapitation at +20 min and +40 min 
after peptide administration. Each value is the mean of 6 ± sem. 
The RIA was performed with reagents distributed by the NIDDK program. 
The TSH levels are recorded in terms of the RP-2 reference standard. 
Receptor bindiQ&' assays. Fresh tissue samples of pituitary and corte.x were 
obtained from male Sprague-Dawley rats. Radioreceptor assa~s were performed 
using (SH)[3-Me-His2]TRH (NEN) as the radioligand (19). Bnefly, tissue sam.ples 
were homogenized (Brinkman Polytron) in 25 vol. of 100 mM sodium phoaphate 
buffer. After centrifugation at 39000 g for 30 min, tbe pellets were resuspended in 
ice-cold buffer containing 177µM bacitracin to a concentration of 50 (pituitary) or 
100 (cortex) mg/ml. The tisaue resuspensions were incubated with 
(SH][3-Me-His2]TRH and increasing analog concentrations at 4 to 6°C for 2.5 h. 
Nonspecific binding was determined in the presence of 10 µM TRH. Tbe 
incubation was tenninated by vacuwn filtration through Whatman GF/B flass 
filters by meana of a 48 well cell harvester (Brandel), followed by 3 rinaes o 4 ml of 
ice-cold 0.9% sodium chloride solution each. Filters were placed in glass 
scintillation vials, immersed in scintillation fluid (Beckman ReadySolv HP) and 
bound radioactivity counted on the following day. Inhibition constants Ki were 
determined according to Cheng and Prusoff (20) using the radioligand binding 
analysis program LIGAND (Elsevier-Biosoft). 
RESULTS AND DISCUSSION 
The results of the in uitro biological activities are reported in Table 1. All 
four of the tripeptides significantly released TSH in uitro. Analog III in which the 
carbonyl oxygen of the pyroglutamyl ring was substituted by sulfur and analog II 
in which the carbonyl oxygen of the carboxyamide at the C terminus was 
substituted by sulfur had essentially the same TSH-releasing activity as the 
parent peptide TRH. Analog IV, with dithio substitutions at the above sites,was 
slightly less active than TRH, II, or III at all three dosages. 
In the in viuo assay (Table 2) the results again demonstrate that all four of 
the tripeptides significantly released TSH. Essentially the same relative degree of 
II 
III 
IV 
TABLE 1. Biological activities in vitro of thionated analogs 
of thyrotropin-releasing hormone 
rTSH nwml±SEM at dose• 
Structure 3 ng 10 ng 30 ng 
Glp-His-Pro-NH2 (TRH) 5.0±0.3 5.0±0.5 5.3±0.1 
Glp-His-Pro1j1[CSNH2l 3.9±0.2 5.0±0 3.9±0.8 
Top-His-Pro-NH2 3.9±0.1 5.6±0 6.0±0.1 
Top-His-Prow[CSNH2l 3.0±0.2 4.0±0.3 3.0±0.8 
a baseline 1.6±0 
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TABLE2. Biological activities in vivo of analoge ofthyrotropin-
releasing hormone 
trSH ng!'.ml±SEM at dose• (40 min)b 
Structure 0.1 µ.g 0.3 µ.g 1.0 µ.g 3 µ.g 1µ.g 
Glp-His-PTO-NH2 (TRH) 11±2 2~ 20±1 30±3 m 
II Glp-His-Pro1J1[CSNH2J l:ltl 16±2 20±3 21±3 7±1 
III Top-His-Pro-NH2 13±2 21±2 24±1 25±3 8tl 
IV Top-His-Prov[CSNH2l 5±2 9±2 2~ 22±1 4±2 
• Female rats: 26 days old; sacrifi~d 20 min after injection; or b 40 min after injection ; n = 6; 
baseline = 0. 7±0.2 
TSH-releasing activity for each peptide was found in vivo andin vitro. When the 
studies were performed at +20 min after injection of the peptide, the TSH-
releasing activities of analogs II and III were nearly the same as that of TRH (I). 
Although analog IV definitely released TSH, it was less active than II, III, or I. 
When the studies were performed at +40 min, the same relative activities were 
observed. 
We next examined the binding of our analogs toward pituitary and cortical 
receptors for TRH (Table 3). The order of decreasing pituitary receptor affinities 
was analog II, TRH and IV, and III, while the values for the CNS cortical 
receptor affinity were TRH > analogs II and III > IV. Thus, of the four peptides, 
the binding of analog II was greatest on pituitary receptor and TRH greatest on 
the cortical receptor. Furthermore, comparison of the Ki CtKi P ratios of these four 
peptides indicates that thionated TRH analogs have been developed that have 
different relative affinities than TRH for the cortex and pituitary receptors. For 
example, the KiCtKiP ratio results of TRH and analog III were the same while 
analogs II and IV were 11- and 15-fold higher than TRH. Even though analog IV 
and TRH bound equally to the pituitary receptor, analog IV binding to the cortex 
receptor was 20-fold less than TRH. In comparison to TRH, analog II binding to 
II 
III 
IV 
TABLE 3. Bimling assaye of thionated analoge of thyrotropin-
releasing hormonea 
Structure 
Glp-His- Pro-NH2 CTRH) 
Glp-His-Prov[CSNH2l 
Top-His-Pro-NH2 
Top-His-Prov!CSNH2J 
PITUITARY 
Relative 
KiP (nM) Potency 
24.1±14.2 1.0 
8 .0±0.2 3.01 
85.4±17.8 0.23 
31.9±2.9 0.76 
CORTEX 
Relative 
K;C (nM) Potency 
26.1±4.5 1.0 
93.1±16.5 0.28 
86.1±6.3 0.30 
501±173 0.05 
11. [[3H]-3-Me-His2]TRH was used as the radioligand. 
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the pituitary receptor was greater and less on the cortex while the binding of 
analog III and TRH was nearly the same on both receptors. 
The biological profiles of the new thionated analogs of TRH thus provide a 
further example of selectivity changes that may be induced through modification 
ofthe peptide backbone. Substitution ofthe one oxygen at the C- or N-terminus 
produced analogs (II and III) that were essentially equipotent in TSH release 
with the natural hormone both in vitro and in vivo. The in vivo biological activity 
of the Pro'lf(CSNH2] analog (II) is similar to that reported by Kruszynski et al. (14). 
However, when a sulfur substitution was made at both the N- and C-termini, the 
TSH-releasing activity was less, particularly at the lower dosages. These results 
are especially interesting when compared with the lipophilicity of the analogs, 
which was determined as a function of their HPLC retention times. The 
monothionated analog (III), with high pituitary receptor binding activity, has the 
shortest retention time (tR = 9.62 min). The Pro'l'fCSNH2] analog (II) is only a 
little more hydrophobic (tR = 9.99 min). The most hydrophobic peptide was the 
dithionated analog IV (tR = 14.59 min), which also happens to show the greatest 
binding selectivity. The retention time ofTRH is 5.17 min. 
TRH has multiple biological effects at various anatomical sites which may 
be mediated via different TRH receptor subtypes (22-25). Previously, we have 
observed that backbone thionation of enkephalins yielded receptor-selective 
analogs (12,15). 
Comparison of the pituitary receptor-binding affinity and TSH-releasing 
activity results of analogs II and Ill were particularly surprising. The pituitary 
affinity of analog III was low and that of analog II was high and yet both released 
an amount ofTSH equal to that of TRH. This result may indicate that the C=S N-
terminal substitution of analog III decreased binding while increasing the 
efficiency and effectiveness of the activation mechanism which mediates TSH 
from the pituitary thyrotrophes. Alternatively, this factor could be the result of 
altered stability of the thio analog toward enzymatic degradation (26). 
Parenthetically, the C=S C-terminal substitution of analog II increased binding 
while not significantly affecting the activation mechanism. As yet, the molecular 
details of how TRH activates the receptor have not been elucidated. The 
paradoxical dual effects of analogs II and III on binding and activation seemingly 
indicate the more global nature of this problem and the difficulty of separating the 
components of the TRH molecule that are selectively responsible for these 
individual effects. The affinity/releasing activity of analog IV with C=S 
substitutions at both the N- and C-t.erminus appears to result in some type of a 
hybrid effect of analogs II and III. The reduction in binding from the N-terminal 
substitution is compensated to a large extent by enhanced binding via C-terminal 
substitution, resulting in essentially similar binding of TRH and analog IV. This 
hybrid effect could be due in part to the considerably greater hydrophobicity of 
analog IV than II or III. 
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The effects observed through C=S substitution may help to guide or impart 
new insights into the chemical mechanisms involved in TRH receptor binding 
and activation. For example, the effects of thionation of the carbonyl-carbon at the 
C-terminal amide may be induced by stronger hydrogen bonding via the NH2 
group while the thionation of the carbonyl carbon of the pyroglutamyl ring may 
decrease hydrogen bonding via reduced acceptor properties of the C=S group. 
Just how the C=S C-terminal substitution might increase activation and decrease 
binding is not readily apparent. However, this may indicate the importance of the 
N-terminus for TRH activation. The increased donor capacity of the thioamide 
NH compared to the parent amide may rationalize this behavior. Alternatively, a 
"packet" for the C=O group on the pituitary receptor may accommodate the C=O 
more readily than the C=S group because ofthe larger size ofthe S than the 0 
atom; however, once the thioamide group is in the "packet" its altered hydrogen 
bonding is more effective and efficient in activating the receptor than the amide. 
Apparently, neither of the hydrogen bonding changes induced by the C=S 
substitutions favors binding of the analogs to the cortical receptor. Whether 
cortical receptor affinities of future TRH analogs might be selectively augmented 
by increasing hydrogen bonding at the N-terminus of TRH and/or by decreasing 
hydrogen bonding at the C-terminus will warrant consideration. 
Overall, the results of these studies provide interesting contributions to 
understanding the influence of the thioamide bond replacement on the activity 
and selectivity ofbiologically active peptides. More specifically, it has been shown 
that thionation of TRH leads to preferential binding to receptors in different 
tissues. This may prove useful for further defining the role and chemical 
mechanisms of TRH receptor binding and activation in various tissues. 
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